NGM·Healthcare·$354M·#132 / 520 in Healthcare
YDES YD Bio Limited
60SOLID
CATEGORY BREAKDOWN
GROWTH73
QUALITY24
STABILITY82
VALUATION0
GOVERNANCE100
METRIC BREAKDOWN
Revenue Growth (YoY)
Year-over-year revenue growth rate
+45.8%
73
> 50% strong
Gross Margin
Revenue retained after direct costs
30.4%
41
> 50% strong
Cash Runway
Months of cash at current burn rate
20 months
73
> 24 months ideal
Debt / Equity
Total debt relative to shareholder equity
0.3%
100
< 25% strong
Price / Sales
Market cap relative to trailing revenue
693.7x
0
< 3x strong
Rule of 40
Growth rate plus operating margin
-241
0
> 40 excellent
Insider Ownership
Percentage of shares held by insiders
81.0%
100
> 20% strong
Share Dilution (12M)
Share count increase over last 12 months
+0.0%
100
< 5% ideal
RELATED STOCKS
COMPARE YDES WITH…
OR QUICK-COMPARE SECTOR PEERS
SCORE ALERT
Get notified when YDES's score changes by 5+ points.
DATA INFO
Last updated: May 4, 2026
Sources: SEC EDGAR, Financial Modeling Prep, Yahoo Finance. Not financial advice.